Skip to main content
SpringerLink
Log in

Strategic Marketing Decision Models for the Pharmaceutical Industry

  • Chapter
Handbook of Marketing Decision Models

Part of the book series: International Series in Operations Research & Management Science ((ISOR,volume 121))

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 259.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Notes

  1. 1.

    The author thank Jeff Meyer and Marie Hollinger for their help as graduate assistants.

  2. 2.

    White Book – U.S. Healthcare: A Mess Central Planning in Capitalism's Backyard; May 2005, pp. 9-14, 6p <Business Source Complete> http://search.ebscohost.com.ezproxy.tamu.edu:2048/login.aspx?direct=true&db=bth&AN=18535978&site=bsi-live

  3. 3.

    Pharmaceutical Industry Profile 2007. Pharmaceutical Research and Manufacturers of America. 2007 < http://www.phrma.org/files/Profile%202007.pdf> Page 25

  4. 4.

    Agovina, Teresa. “Global Pharmaceutical Sales Up 7 Pct.” Associated Press. 2007 Mar 20 <http://www.forbes.com/feeds/ap/2007/03/20/ap3535773.html>

  5. 5.

    Pharmaceutical Industry Profile 2007. Pharmaceutical Research and Manufacturers of America. 2007 <http://www.phrma.org/files/Profile%202007.pdf>

  6. 6.

    White Book - U.S. Healthcare: A Mess Central Planning in Capitalism's Backyard; May2005, pp. 9-14, 6p <Business Source Complete> http://search.ebscohost.com.ezproxy.tamu.edu:2048/login.aspx?direct=true&db=bth&AN=18535978&site=bsi-live

  7. 7.

    Economic Intelligence Unit. “Regional and Country Data.” 3/27/2006 <Business Source Complete> http://search.ebscohost.com.ezproxy.tamu.edu:2048/login.aspx?direct=true&db=bth&AN=20396424&site=bsi-live

  8. 8.

    http://www.jpma.or.jp/english/library/index.html, Pharmaceutical Industry Profile 2007. Pharmaceutical Research and Manufacturers of America. 2007 <http://www.phrma.org/files/Profile%202007.pdf>

  9. 9.

    Pharmaceutical Industry Profile 2007. Pharmaceutical Research and Manufacturers of America. 2007 <http://www.phrma.org/files/Profile%202007.pdf>

  10. 10.

    Pharmaceutical Industry Profile 2007. Pharmaceutical Research and Manufacturers of America. 2007 <http://www.phrma.org/files/Profile%202007.pdf>

References

  • Agarwal, S., S. Desai, M.H. Holcomb, A. Oberoi. 2001. Unlocking the Value in Big Pharma. McKinsey Quarterly 2 65–73.

    Google Scholar 

  • Berndt, E.R. 2006. The United States’ Experience with Direct-to-Consumer Advertising of Prescription Drugs: What have we Learned? Chapter 9, in Sloan, F.A., C.-R. Hsieh, Promoting and Coping with Pharmaceutical Innovation: An International Perspective. Cambridge University Press, Cambridge MA.

    Google Scholar 

  • Caciotti, J., B. Shew. 2006. Pharma’s Next Top Model. Pharmaceutical Executive 26(3) 82–86.

    Google Scholar 

  • Chintagunta, P.K., R. Desiraju. 2005. Strategic Pricing and Detailing Behavior in International Markets. Marketing Science 24(1) 67–80.

    Article  Google Scholar 

  • Danzon P., S. Nicholson, N.S. Pereira. 2005. Productivity in Pharmaceutical-Biotechnology R&D: the Role of Experience and Alliances. Journal of Health Economics 24 317–339.

    Article  Google Scholar 

  • Dekimpe, M.G., D.M. Hanssens. 1999. Sustained Spending and Persistent Response: A New Look at Long-Term Marketing Profitability. Journal of Marketing Research 36(4) 397–412.

    Article  Google Scholar 

  • DiMasi, J.A., R.W. Hansen, H.G. Grabowski. 2003. The Price of Innovation: New Estimates of Drug Development Costs.Journal of Health Economics 151–185.

    Google Scholar 

  • Ding, M., J. Eliashberg. 2002. Structuring the New Product Development Pipeline. Management Science 48(3) 343–63.

    Article  Google Scholar 

  • Ding, M., J. Eliashberg. 2008. A Dynamic Competitive Forecasting Model Incorporating Dyadic Decision-Making. Management Science 54(4) 820–834.

    Google Scholar 

  • Fischer, M., V. Shankar, M. Clement. 2005. Can a Late Mover Use International Market Entry Strategy to Challenge the Pioneer? MSI Report No. 05-004, 25–48. Marketing Science Institute, Cambridge: MA.

    Google Scholar 

  • Gatignon, H., E. Anderson, K. Helsen. 1989. Competitive Reactions to Market Entry: Explaining Interfirm Differences. Journal of Marketing Research 26(1) 44–55.

    Article  Google Scholar 

  • Gatignon, H., B. Weitz, P. Bansal. 1990. Brand Introduction Strategies and Competitive Environments. Journal of Marketing Research 27(4) 390–401.

    Article  Google Scholar 

  • Grabowski, H., J. Vernon. 1990. A New Look at the Returns and Risks to Pharmaceutical R&D. Management Science 36(7) 804–821.

    Article  Google Scholar 

  • Grabowski, H., J. Vernon, J.A. Dimasi. 2002. Returns on Research and Development for 1990s New Drug Introductions. Pharmacoeconomics 20(3) 11–29.

    Article  Google Scholar 

  • Grewal, R., M. Ding, J. Liechty. 2006. Evaluating New Product Portfolio Strategies. Working Paper. Penn State University, PA.

    Google Scholar 

  • Gönül, F.F., K. Srinivasan. 2001. Promotion of Prescription Drugs and Its Impact on Physicians' Choice Behavior. Journal of Marketing 65(3) 79–90.

    Article  Google Scholar 

  • Hahn, M., S. Park, L. Krishnamurthi, A. Zoltners. 1994. Analysis Of New Product Diffusion Using A Four Segment Trial-Repeat Model. Marketing Science 13(3) 224–247.

    Article  Google Scholar 

  • Hoover’s .2006. Hoover’s Index.

    Google Scholar 

  • IMS Health 2006. IMS Retail Drug Monitor. December.

    Google Scholar 

  • Kalaignanam, Kartik, V. Shankar, R. Varadarajan. 2007. To End or Extend: An Empirical Analysis of Determinants of New Product Development Alliance Terminations. Working Paper. Texas A&M University, TX.

    Google Scholar 

  • Lee, J. 2003. Innovation and Strategic Divergence: An Empirical Study of the U.S. Pharmaceutical Industry from 1920 to 1960. Management Science 49(2) 143–159.

    Google Scholar 

  • Lilien, G.L., A.G. Rao, S. Kalish. 1981. Bayesian Estimation And Control Of Detailing Effort In A Repeat Purchase Diffusion Environment. Management Science 27(5) 493–506.

    Article  Google Scholar 

  • Manchanda, P., P.K. Chintagunta. 2004. Responsiveness of Physician Prescription Behavior to Sales force Effort: An Individual Level Analysis. Marketing Letters 15(2–3) 129–145.

    Article  Google Scholar 

  • Manchanda, P., P.E. Rossi, P.K. Chintagunta. 2004. Response Modeling with Nonrandom Marketing-Mix Variables. Journal of Marketing Research 41(4) 467–478.

    Google Scholar 

  • Manchanda, P., P.E. Rossi, P.K. Chintagunta. 2004. Response Modeling with Nonrandom Marketing-Mix Variables. Journal Of Marketing Research 41(4) 467–478.

    Article  Google Scholar 

  • Manchanda, P., E. Honka. 2005. The Effects and Role of Direct-to-Physician Marketing in the Pharmaceutical Industry: An Integrative Review. Yale Journal of Health Policy, Law and Ethics 2 785–822.

    Google Scholar 

  • Mantrala, M.K., P. Sinha, A. Zoltners. 1994. Structuring A Multiproduct Sales Quota-Bonus Plan for A Heterogeneous Sales Force: A Practical Model-Based Approach. Marketing Science 13(2) 121–44.

    Article  Google Scholar 

  • Mizik, N., R. Jacobson. 2004. Are Physicians 'Easy Marks'?: Quantifying the Effects of Detailing and Sampling on New Prescriptions. Management Science 50(12) 1704–1715.

    Article  Google Scholar 

  • Montgomery, D.B., A.J. Silk 1972. Estimating Dynamic Effects of Market Communications Expenditures. Management Science 18(10) B485–B501.

    Article  Google Scholar 

  • Narayanan, S., P. Manchanda, P.K. Chintagunta. 2005. Temporal Differences in the Role of Marketing Communication in New Product Categories. Journal of Marketing Research 42(3) 278–290.

    Article  Google Scholar 

  • Narayanan, S., R. Desiraju, P.K. Chintagunta. 2004. Return on Investment Implications for Pharmaceutical Promotional Expenditures: The Role of Marketing-Mix Interactions. Journal of Marketing 68(4) 90–105.

    Article  Google Scholar 

  • Neslin, S.A. 2001. ROI Analysis of Pharmaceutical Promotion (RAPP): An Independent Study. Association of Medical Publications, (accessed October 26, 2005), [available at http://www.rxpromoroi.org/rappl/]

  • PhRMA .2007. Pharmaceutical Industry Profile Pharmaceutical Research and Manufacturers of America, http://www.phrma.org/files/Profile%202007.pdf.

  • Rangaswamy, A., L. Krishnamurthi. 1991. Response Function Estimation Using the Equity Estimator. Journal of Marketing Research 28(1) 72–83.

    Article  Google Scholar 

  • Rangaswamy, A., P. Sinha, A. Zoltners. 1990. An Integration Model-Based Approach for Sales Force Structuring. Marketing Science 9(4) 279–98.

    Article  Google Scholar 

  • Rao, A.G., M. Yamada. 1988. Forecasting With A Repeat Purchase Diffusion Model. Management Science 34(6) 734–752.

    Article  Google Scholar 

  • Shankar, V. 1997. Pioneers’ Marketing Mix Reactions to Entry in Different Competitive Games Structures: Theoretical Analysis and Empirical Illustration. Marketing Science 16(4) 271–293.

    Article  Google Scholar 

  • Shankar, V. 1999. New Product Introduction and Incumbent Response Strategies: Their Interrelationship and the Role of Multimarket Contact. Journal of Marketing Research 36(3) 327–344.

    Article  Google Scholar 

  • Shankar, V. 2008. The Role of Product Life Cycle and Market Dominance in Marketing Expenditures of Products. Working Paper. Texas A&M University, TX.

    Google Scholar 

  • Shankar, V., G.S. Carpenter, L. Krishnamurthi. 1998. Late Mover Advantage: How Innovative Late Entrants Outsell Pioneers. Journal of Marketing Research 35(1) 54–70.

    Article  Google Scholar 

  • Shankar, V., G.S. Carpenter, L. Krishnamurthi 1999. The Advantages of Entry in the Growth Stage of the Product Life Cycle: An Empirical Analysis. Journal of Marketing Research 36(2) 269–276.

    Article  Google Scholar 

  • Singh, A., P. Henske 2003. Has the Pharmaceutical Blockbuster Model Gone Bust? Bain & Company Report.

    Google Scholar 

  • Sorescu, A.B., R.K. Chandy, J.C. Prabhu. 2003. Sources and Financial Consequences of Radical Innovation: Insights from Pharmaceuticals. Journal of Marketing, 67(4) 82–102.

    Article  Google Scholar 

  • Trombetta, B. 2007. Industry Audit. Pharmaceutical Executive, September.

    Google Scholar 

  • Wierenga, B., G.H. van Bruggen, R. Staelin. 1999. The Success of Marketing Management Support Systems. Marketing Science 18(3) 196–207.

    Article  Google Scholar 

  • Wosinska, M. 2005. Direct-to-Consumer Advertising and Drug Therapy Compliance. Journal of Marketing Research 42(3) 323–332.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Mays Business School, Texas A&M University, College Station, Texas 77845, USA

    Venkatesh Shankar

Authors
  1. Venkatesh Shankar
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Venkatesh Shankar .

Editor information

Editors and Affiliations

  1. Erasmus University, Rotterdam, The Netherlands

    Berend Wierenga (Prof) (Prof)

Rights and permissions

Reprints and permissions

Copyright information

© 2008 Springer Science+Business Media, LLC

About this chapter

Cite this chapter

Shankar, V. (2008). Strategic Marketing Decision Models for the Pharmaceutical Industry. In: Wierenga, B. (eds) Handbook of Marketing Decision Models. International Series in Operations Research & Management Science, vol 121. Springer, Boston, MA. https://doi.org/10.1007/978-0-387-78213-3_14

Download citation

Publish with us

Policies and ethics

Search

Navigation